drugset / Trial / NCT00529867

Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria

NCT00529867

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and efficacy in children aged 6 - 59 months with uncomplicated malaria, treated with either conventional artemether/lumefantrine tablets(Coartem®) or artemether/ lumefantrine suspension (Co-artesiane®) in Western Kenya

Timeline

Start
2007-05
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Artemether Small molecule 20 mg Oral
Comparator Artemether Small molecule 21 mg Oral
Comparator Artemether Small molecule 30 mg Oral
Comparator Artemether Small molecule 40 mg Oral
Comparator Artemether Small molecule 42 mg Oral
Comparator Artemether Small molecule 51 mg Oral
Comparator Artemether Small molecule 60 mg Oral
Comparator Artemether Small molecule 72 mg Oral
Comparator Artemether Small molecule 81 mg Oral
Comparator Artemether Small molecule 90 mg Oral
Comparator lumefantrine Small molecule 120 mg Oral
Comparator lumefantrine Small molecule 126 mg Oral
Comparator lumefantrine Small molecule 180 mg Oral
Comparator lumefantrine Small molecule 240 mg Oral
Comparator lumefantrine Small molecule 252 mg Oral
Comparator lumefantrine Small molecule 306 mg Oral
Comparator lumefantrine Small molecule 360 mg Oral
Comparator lumefantrine Small molecule 432 mg Oral
Comparator lumefantrine Small molecule 486 mg Oral
Comparator lumefantrine Small molecule 540 mg Oral